BRAF and odontogenic neoplasm: Although targeted therapy has mainly focused on ameloblastomas, further in vitro and in vivo studies, and clinical trials may help to establish standardized therapeutic regimens both for ameloblastomas and other BRAF mutation-positive odontogenic tumors.